ARTICLE | Clinical News
Aranesp misses endpoints in diabetes patients
August 25, 2009 11:53 PM UTC
Amgen Inc. (NASDAQ:AMGN) said top-line data from the Phase III TREAT trial in 4,038 chronic kidney disease (CKD) patients with Type II diabetes and anemia showed that Aranesp darbepoetin alfa missed t...